Innate Lymphoid Cells: A Promising New Regulator in Fibrotic Diseases

International Reviews of Immunology

Volumn 35, Issue 5, 2016, Pages 399-414

  Zhang, Yi ^a   Tang, Jun ^b   Tian, Zhiqiang ^a   van Velkinburgh, Jennifer C ^c   Song, Jianxun ^d   Wu, Yuzhang ^a   Ni, Bing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The 105th Hospital of PLA   (China)

^c Van Velkinburgh Initiative for Collaboratory BioMedical Research   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

chronic inflammation; fibrosis; hepatic fibrosis; innate lymphoid cells; interleukin; pulmonary fibrosis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

FIBROSIS; HUMAN; LIVER FIBROSIS; LUNG FIBROSIS; LYMPHOID CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; ADAPTIVE IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LIVER; LYMPHOCYTE; PATHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; FIBROSIS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; INFLAMMATION; LIVER; LYMPHOCYTES; PULMONARY FIBROSIS;

EID: 84939478290     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2015.1068304     Document Type: Review

References (134)

1. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 2007;117:524–529, doi:10.1172/JCI31487.
2. Tomasek JJ, Gabbiani G, Hinz B, Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature reviews. Mol Cell Biol 2002;3:349–363, doi:10.1038/nrm809.
3. Ueha S, Shand FH, Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol 2012;3:71, doi:10.3389/fimmu.2012.00071.
4. Raghu G, Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older:incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2014;2:566–572, doi:10.1016/S2213-2600(14)70101-8.
5. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–218, doi:10.1172/JCI24282.
6. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199–210, doi:10.1002/path.2277.
7. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011;7:684–696, doi:10.1038/nrneph.2011.149.
8. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007;117:530–538, doi:10.1172/JCI30595.
9. McKenzie AN, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity 2014;41:366–374, doi:10.1016/j.immuni.2014.09.006.
10. Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity 2014;41:354–365, doi:10.1016/j.immuni.2014.09.005.
11. Cortez VS, Robinette ML, Colonna M. Innate lymphoid cells:new insights into function and development. Curr Opin Immunol 2015;32:71–77, doi:10.1016/J.Coi.2015.01.004.
12. Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells—how did we miss them? Nature reviews. Immunology 2013;13:75–87, doi:10.1038/nri3349.
13. Klose CS, Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell 2014;157:340–356, doi:10.1016/j.cell.2014.03.030.
14. Daussy C, T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. J Exp Med 2014;211:563–577, doi:10.1084/Jem.20131560.
15. Klose CS, A T-bet gradient controls the fate and function of CCR6-RORgammat +innate lymphoid cells. Nature 2013;494:261–265, doi:10.1038/nature11813.
16. Sciume G, Distinct requirements for T-bet in gut innate lymphoid cells. J Exp Med 2012;209:2331–2338, doi:10.1084/jem.20122097.
17. Rankin LC, The transcription factor T-bet is essential for the development of NKp46+ innate lymphocytes via the Notch pathway. Nat Immunol 2013;14:389–395, doi:10.1038/ni.2545.
18. Rehermann B. Pathogenesis of chronic viral hepatitis:differential roles of T cells and NK cells. Nat Med 2013;19:859–868, doi:10.1038/nm.3251.
19. Deguine J, Bousso P. Dynamics of NK cell interactions in vivo. Immunol Rev 2013;251:154–159, doi:10.1111/imr.12015.
20. Liang HE, Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2012;13:58–66, doi:10.1038/ni.2182.
21. Moro K, Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010;463:540–544, doi:10.1038/nature08636.
22. Fort MM, IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001;15:985–995.
23. Hurst SD, New IL-17 family members promote Th1 or Th2 responses in the lung:in vivo function of the novel cytokine IL-25. J Immunol 2002;169:443–453.
24. Wilhelm C, An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011;12:1071–1077, doi:10.1038/ni.2133.
25. Licona-Limon P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol 2013;14:536–542, doi:10.1038/ni.2617.
26. Spits H, Innate lymphoid cells–a proposal for uniform nomenclature. Nature reviews. Immunology 2013;13:145–149, doi:10.1038/nri3365.
27. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Ann Rev Immunol 2005;23:487–513, doi:10.1146/annurev.immunol.23.021704.115732.
28. Hamada H, Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol 2002;168:57–64.
29. Bouskra D, Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008;456:507–510, doi:10.1038/nature07450.
30. Scandella E, Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat Immunol 2008;9:667–675, doi:10.1038/ni.1605.
31. Kim MY, Function of CD4+CD3- cells in relation to B- and T-zone stroma in spleen. Blood 2007;109:1602–1610, doi:10.1182/blood-2006-04-018465.
32. Hwang YY, McKenzie AN. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol 2013;785:9–26, doi:10.1007/978-1-4614-6217-0_2.
33. Luzina IG, Todd NW, Sundararajan S, Atamas SP. The cytokines of pulmonary fibrosis:Much learned, much more to learn. Cytokine 2015; 74:88–100, doi:10.1016/j.cyto.2014.11.008.
34. Todd NW, Luzina IG, Atamas SP. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis & Tissue Repair 2012;5:11, doi:10.1186/1755-1536-5-11.
35. Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM. Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 2004;30:339–349, doi:10.1385/IR:30:3:339.
36. Jakubzick C, Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J Immunol 2003;171:2684–2693.
37. Brunner SM, IL-13 signaling via IL-13Ralpha2 triggers TGF-beta1-dependent allograft fibrosis. Transplant Res 2013;2:16, doi:10.1186/2047-1440-2-16.
38. Luzina IG, Regulation of inflammation by interleukin-4:a review of “alternatives”. J Leukoc Biol 2012;92:753–764, doi:10.1189/jlb.0412214.
39. Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine 2011;56:544–549, doi:10.1016/j.cyto.2011.08.030.
40. Kolodsick JE, Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172:4068–4076.
41. Gharaee-Kermani M, Nozaki Y, Hatano K, Phan SH. Lung interleukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine 2001;15:138–147, doi:10.1006/cyto.2001.0903.
42. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479–1485, doi:10.1172/JCI116015.
43. Rankin AL, IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010;184:1526–1535, doi:10.4049/jimmunol.0903306.
44. Hams E, IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl Acad Sci USA 2014;111:367–372, doi:10.1073/pnas.1315854111.
45. McHedlidze T, Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity 2013;39:357–371, doi:10.1016/j.immuni.2013.07.018.
46. Li D, IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 2014;134:1422–1432 e1411, doi:10.1016/j.jaci.2014.05.011.
47. Li J, Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation. J Clin Invest 2014;124:3241–3251, doi:10.1172/JCI73742.
48. Sanchez-Mas J, Modulation of IL-33/ST2 system in postinfarction heart failure:correlation with cardiac remodelling markers. Eur J Clin Invest 2014;44:643–651, doi:10.1111/eci.12282.
49. Seki K, Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circulation. Heart Failure 2009;2:684–691, doi:10.1161/CIRCHEARTFAILURE.109.873240.
50. Sanada S, IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538–1549, doi:10.1172/JCI30634.
51. Saenz SA, IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010;464:1362-U1368, doi:10.1038/Nature08901.
52. Schmitz J, IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479–490, doi:10.1016/J.Immuni.2005.09.015.
53. Pichery M, Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues:in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012;188:3488–3495, doi:10.4049/Jimmunol.1101977.
54. Carriere V, IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007;104:282–287, doi:10.1073/Pnas.0606854104.
55. Spits H, Di Santo JP. The expanding family of innate lymphoid cells:regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011;12:21–27, doi:10.1038/Ni.1962.
56. Oboki K, IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA 2010;107:18581–18586, doi:10.1073/Pnas.1003059107.
57. Kurowska-Stolarska M, IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009;183:6469–6477, doi:10.4049/Jimmunol.0901575.
58. Kurowska-Stolarska M, IL-33 induces antigen-specific IL-5(+) T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008;181:4780–4790.
59. Humphreys NE, Xu D, Hepworth MR, IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008;180:2443–2449.
60. Luzina IG, Full-Length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashion. J Immunol 2012;189:403–410, doi:10.4049/Jimmunol.1200259.
61. Khan SB, Antibody blockade of TNF-alpha reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int 2005;67:1812–1820, doi:10.1111/j.1523-1755.2005.00279.x.
62. Tarrats N, Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis. Hepatology 2011;54:319–327, doi:10.1002/hep.24388.
63. Sime PJ, Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts. Am J Pathol 1998;153:825–832.
64. Chou DH, Lee W, McCulloch CA. TNF-alpha inactivation of collagen receptors:implications for fibroblast function and fibrosis. J Immunol 1996;156:4354–4362.
65. Wynn TA., Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4:583–594, doi:10.1038/nri1412.
66. Gao B, Radaeva S, Jeong WI. Activation of natural killer cells inhibits liver fibrosis:a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 2007;1:173–180, doi:10.1586/17474124.1.1.173.
67. Muhanna N, Activation of hepatic stellate cells after phagocytosis of lymphocytes:A novel pathway of fibrogenesis. Hepatology 2008;48:963–977, doi:10.1002/hep.22413.
68. Sonnenberg GF, Fouser LA, Artis D. Border patrol:regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011;12:383–390, doi:10.1038/Ni.2025.
69. Huber S, IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 2012;491:259–263, doi:10.1038/nature11535.
70. Perry JS, Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 2012;4:145ra106, doi:10.1126/scitranslmed.3004140.
71. Mair F, Becher B. Thy1+ Sca1+ innate lymphoid cells infiltrate the CNS during autoimmune inflammation, but do not contribute to disease development. Eur J Immunol 2014;44:37–45, doi:10.1002/eji.201343653.
72. Villanova F, Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44 +ILC3 in psoriasis. J Invest Dermatol 2014;134:984–991, doi:10.1038/jid.2013.477.
73. Kim HY, Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat Med 2014;20:54–61, doi:10.1038/nm.3423.
74. Simonian PL, gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med 2010;207:2239–2253, doi:10.1084/jem.20100061.
75. Liang M, Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis. Mediat Inflamm 2013;2013;209179, doi:10.1155/2013/209179.
76. Kong X, Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012;56:1150–1159, doi:10.1002/hep.25744.
77. Kronenberger B, Interleukin-22 predicts severity and death in advanced liver cirrhosis:a prospective cohort study. BMC Med 2012;10:102, doi:10.1186/1741-7015-10-102.
78. Seki E, Schwabe RF. Hepatic inflammation and fibrosis:functional links and key pathways. Hepatology 2015; 61:1066–1079, doi:10.1002/hep.27332.
79. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997;8:253–265.
80. Wilson MS, Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med 2010;207:535–552, doi:10.1084/jem.20092121.
81. Hoshino T, Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol 2009;41:661–670, doi:10.1165/rcmb.2008-0182OC.
82. Kolb M, Margetts PJ, Anthony DC, Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529–1536, doi:10.1172/JCI12568.
83. Postlethwaite AE, Lachman LB, Kang AH. Induction of fibroblast proliferation by interleukin-1 derived from human monocytic leukemia cells. Arthritis Rheum 1984;27:995–1001.
84. Bhatnagar R, Interleukin-1 inhibits the synthesis of collagen by fibroblasts. Biochem Int 1986;13:709–720.
85. Mia MM, Boersema M, Bank RA. Interleukin-1beta attenuates myofibroblast formation and extracellular matrix production in dermal and lung fibroblasts exposed to transforming growth factor-beta1. PloS One 2014;9:e91559, doi:10.1371/journal.pone.0091559.
86. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139–145, doi:10.1038/nm1551.
87. Simonian PL, Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 2009;182:657–665.
88. Meng F, Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012;143:765–776 e761–763, doi:10.1053/j.gastro.2012.05.049.
89. Tan Z, IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol 2013;191:1835–1844, doi:10.4049/jimmunol.1203013.
90. Lo Re S, IL-17A-producing gammadelta T and Th17 lymphocytes mediate lung inflammation but not fibrosis in experimental silicosis. J Immunol 2010;184:6367–6377, doi:10.4049/jimmunol.0900459.
91. Nakashima T, Impaired IL-17 signaling pathway contributes to the increased collagen expression in scleroderma fibroblasts. J Immunol 2012;188:3573–3583, doi:10.4049/jimmunol.1100591.
92. Neill DR, Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:1367–1370, doi:10.1038/nature08900.
93. Oliphant CJ, MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic Helminth expulsion. Immunity 2014;41:283–295, doi:10.1016/j.immuni.2014.06.016.
94. Price AE, Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010;107:11489–11494, doi:10.1073/pnas.1003988107.
95. Chang YJ, Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011;12:631–638, doi:10.1038/ni.2045.
96. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012;36:451–463, doi:10.1016/j.immuni.2011.12.020.
97. Hams E, Locksley RM, McKenzie AN, Fallon PG. Cutting edge:IL-25 elicits innate lymphoid type 2 and type II NKT cells that regulate obesity in mice. J Immunol 2013;191:5349–5353, doi:10.4049/jimmunol.1301176.
98. Stanya KJ, Direct control of hepatic glucose production by interleukin-13 in mice. J Clin Invest 2013;123:261–271, doi:10.1172/JCI64941.
99. Weiler-Normann C, Herkel J, Lohse AW. Mouse models of liver fibrosis. Zeitschrift Fur Gastroenterologie 2007;45:43–50, doi:10.1055/s-2006-927387.
100. Wasmuth HE, Tacke F, Trautwein C. Chemokines in liver inflammation and fibrosis. Semin Liver Dis 2010;30:215–225, doi:10.1055/s-0030-1255351.
101. Marvie P, Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010;14:1726–1739, doi:10.1111/j.1582-4934.2009.00801.x.
102. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339–1350, doi:10.1084/jem.20110551.
103. Kraft M. Asthma phenotypes and interleukin-13—moving closer to personalized medicine. New Engl J Med 2011;365:1141–1144, doi:10.1056/NEJMe1108666.
104. Fallon PG, Richardson EJ, McKenzie GJ, McKenzie AN. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13:IL-13 is a profibrotic agent. J Immunol 2000;164:2585–2591.
105. Chiaramonte MG, IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999;162:920–930.
106. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. American journal of physiology. Gastrointest Liver Physiol 2011;300:G723–G728, doi:10.1152/ajpgi.00414.2010.
107. Fallon PG, Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of Helminth expulsion. J Exp Med 2006;203:1105–1116, doi:10.1084/jem.20051615.
108. Saenz SA, IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010;464:1362–1366, doi:10.1038/nature08901.
109. Mjosberg JM, Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011;12:1055–1062, doi:10.1038/ni.2104.
110. Angkasekwinai P, Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007;204:1509–1517, doi:10.1084/jem.20061675.
111. Ballantyne SJ, Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol 2007;120:1324–1331, doi:10.1016/j.jaci.2007.07.051.
112. Luzina IG, Interleukin-33 potentiates bleomycin-induced lung injury. Am J Respir Cell Mol Biol 2013;49:999–1008, doi:10.1165/rcmb.2013-0093OC.
113. Bailey JR, IL-13 promotes collagen accumulation in Crohn's disease fibrosis by down-regulation of fibroblast MMP synthesis:a role for innate lymphoid cells? PloS One 2012;7:e52332, doi:10.1371/journal.pone.0052332.
114. Li C, Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther 2014;16, doi:Artn R105 Doi 10.1186/Ar4554.
115. Liu L, CD4+ T Lymphocytes, especially Th2 cells, contribute to the progress of renal fibrosis. Am J Nephrol 2012;36:386–396, doi:10.1159/000343283.
116. Pavkova Goldbergova M, Relation of IL-6, IL-13 and IL-15 gene polymorphisms to the rheumatoid factors, anti-CCP and other measures of rheumatoid arthritis activity. Int J Immunogenet 2014;41:34–40, doi:10.1111/iji.12065.
117. Yamada D, IL-33 facilitates oncogene induced cholangiocarcinoma in mice by an IL-6 sensitive mechanism. Hepatology 2015; doi:10.1002/hep.27687.
118. Jeong WI, Suppression of innate immunity (natural killer cell/interferon-gamma) in the advanced stages of liver fibrosis in mice. Hepatology 2011;53:1342–1351, doi:10.1002/hep.24190.
119. Baroni GS, Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996;23:1189–1199, doi:10.1002/hep.510230538.
120. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells:immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009;86:513–528, doi:10.1189/JLB.0309135.
121. Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008;134:248–258, doi:10.1053/j.gastro.2007.09.034.
122. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 2006;44:1441–1451, doi:10.1002/hep.21419.
123. Kramer B, Natural killer p46High expression defines a natural killer cell subset that is potentially involved in control of hepatitis C virus replication and modulation of liver fibrosis. Hepatology 2012;56:1201–1213, doi:10.1002/hep.25804.
124. Wick G, The immunology of fibrosis:innate and adaptive responses. Trends Immunol 2010;31:110–119, doi:10.1016/j.it.2009.12.001.
125. Shimoda S, Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology 2011;53:1270–1281, doi:10.1002/hep.24194.
126. Crellin NK, Trifari S, Kaplan CD, Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010;207:281–290, doi:10.1084/jem.20091509.
127. Bernink JH, Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013;14:221–229, doi:10.1038/ni.2534.
128. Fuchs A, Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 2013;38:769–781, doi:10.1016/j.immuni.2013.02.010.
129. Mallat A, Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003–1010.
130. Mebius RE, Rennert P, Weissman IL. Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity 1997;7:493–504.
131. Cella M, A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009;457:722–725, doi:10.1038/nature07537.
132. Zheng Y, Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008;14:282–289, doi:10.1038/nm1720.
133. Melhem A, Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. J Hepatol 2006;45:60–71, doi:10.1016/j.jhep.2005.12.025.
134. Zhang L, Association of interleukin 1 family with systemic sclerosis. Inflammation 2014;37:1213–1220, doi:10.1007/s10753-014-9848-7.